Literature DB >> 2428079

Both somatostatin and the caudal neuropeptide, urotensin II, stimulate lipid mobilization from coho salmon liver incubated in vitro.

M A Sheridan, H A Bern.   

Abstract

The direct effects of somatostatin-14 (SRIF; synthetic ovine) and the fish caudal neuropeptide, urotensin II (UII; synthetic Gillichthys), on fatty acid (FA) release and on lipolytic enzyme (triacylglycerol lipase) activity were determined on coho salmon liver slices incubated in vitro. FA release was continuously measured by pH-stat titration. Additionally, gas chromatographic analysis of the incubation medium was performed to determine the type and relative composition of medium fatty acid constituents. SRIF and UII both stimulated FA release in a dose-dependent manner; the two peptides appeared to stimulate FA release in an equimolar manner. Maximal response was obtained at 1 X 10(-5) M; ED50 was approximately 2 X 10(-7) M. SRIF-stimulated FA release did not result in differential secretion of any particular FA type. Tissue triacylglycerol lipase activity was significantly enhanced by addition of UII or SRIF (2 X 10(-6) M). Dibutyryl cAMP and IBMX both stimulated FA release and lipase activity; dbcAMP stimulated FA release in dose-dependent manner. These results indicate that SRIF and UII directly enhance lipid mobilization from salmon liver slices and suggest that SRIF- and UII-stimulated lipid mobilization from salmon liver slices is mediated through cAMP.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2428079     DOI: 10.1016/0167-0115(86)90175-8

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  8 in total

1.  Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey.

Authors:  S A Douglas; A C Sulpizio; V Piercy; H M Sarau; R S Ames; N V Aiyar; E H Ohlstein; R N Willette
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

2.  Effects of chemical and handling exposure on fatty acids, oxidative stress and morphological welfare indicators in gilt-head sea bream (Sparus aurata).

Authors:  María José Sánchez-Muros; Salvador Villacreces; Genaro Miranda-de la Lama; Carolina de Haro; Fernando García-Barroso
Journal:  Fish Physiol Biochem       Date:  2012-09-26       Impact factor: 2.794

Review 3.  Urotensin-II and cardiovascular diseases.

Authors:  Nicolas Bousette; Adel Giaid
Journal:  Curr Hypertens Rep       Date:  2006-12       Impact factor: 5.369

4.  Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice.

Authors:  David J Behm; Stephen M Harrison; Zhaohui Ao; Kristeen Maniscalco; Susan J Pickering; Evelyn V Grau; Tina N Woods; Robert W Coatney; Christopher P A Doe; Robert N Willette; Douglas G Johns; Stephen A Douglas
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

5.  Identification and pharmacological characterization of native, functional human urotensin-II receptors in rhabdomyosarcoma cell lines.

Authors:  Stephen A Douglas; Diane Naselsky; Zhaohui Ao; Jyoti Disa; Christopher L Herold; Frank Lynch; Nambi V Aiyar
Journal:  Br J Pharmacol       Date:  2004-06-21       Impact factor: 8.739

6.  Physiology of fish endocrine pancreas.

Authors:  E M Plisetskaya
Journal:  Fish Physiol Biochem       Date:  1989-06       Impact factor: 2.794

7.  Raised plasma urotensin II in type 2 diabetes patients is associated with the metabolic syndrome phenotype.

Authors:  Damien Gruson; Michel F Rousseau; Jean-Marie Ketelslegers; Michel P Hermans
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-08       Impact factor: 3.738

8.  A closer look at the role of urotensin II in the metabolic syndrome.

Authors:  Pierre-Olivier Barrette; Adel Giaid Schwertani
Journal:  Front Endocrinol (Lausanne)       Date:  2012-12-28       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.